| Registered | 25 |
| Not treated | 1 |
| Evaluable | 24 |
| Male/female | 13/11 |
| Age median (range) | 49 yr (19-76) |
| WBC median (range) | 1.3 × 109/L (0.3-3.92) |
| RBC median (range) | 3.59 × 1012/L (2.30-4.46) |
| Platelet median (range) | 71 × 109/L (10-153) |
| Blasts in BM | |
| median (range) | 60% (14-96) |
| Fibrinogen median (range) | 2.23 g/L (0.68-5.37) |
| Interval from the last ATRA | |
| median (range) | 22 mo (3-58) |
| Registered | 25 |
| Not treated | 1 |
| Evaluable | 24 |
| Male/female | 13/11 |
| Age median (range) | 49 yr (19-76) |
| WBC median (range) | 1.3 × 109/L (0.3-3.92) |
| RBC median (range) | 3.59 × 1012/L (2.30-4.46) |
| Platelet median (range) | 71 × 109/L (10-153) |
| Blasts in BM | |
| median (range) | 60% (14-96) |
| Fibrinogen median (range) | 2.23 g/L (0.68-5.37) |
| Interval from the last ATRA | |
| median (range) | 22 mo (3-58) |